The European Commission has approved Merck's (MRK) KEYTRUDA plus Paclitaxel with or without Bevacizumab for the treatment of adults with PD-L1 platinum-resistant recurrent ovarian cancer

The European Commission's approval for Merck's KEYTRUDA treatment marks a significant milestone for the company, potentially boosting its revenues in the oncology market. This development could enhance investor sentiment towards Merck and the broader pharmaceutical sector, particularly as it addresses an unmet medical need in recurrent ovarian cancer patients. Market participants may also be evaluating implications for Merck's competitiveness against other players in the oncology space.